Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-associated antigens (TAAs) are molecules, often proteins or glycoproteins, that are present at elevated levels on the surface of tumor cells but can also be found, typically at lower levels, on some normal cells. TAAs are not exclusive to tumors but show preferential or overexpression in malignant tissues, making them targets for immunotherapy and diagnostic applications. They include oncofetal antigens, overexpressed proteins, cancer-testis antigens, lineage-restricted antigens, and mutated/posttranslationally altered forms. While targeting TAAs has led to advances in cancer treatment, their presence on some healthy tissues means that side effects due to off-target toxicity remain a concern.
Therapeutic antibodies or CAR-T cells target TAA-expressing tumor cells, leading to cell death or immune-mediated destruction.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-Associated Antigen (None).